A novel recombinant, VPAC2-selective agonist enhancing insulin release and glucose disposal

Acta Pharmacologica Sinica

Volumn 28, Issue 4, 2007, Pages 526-533

  Yu, Rong Jie ^a   Tam, Ngai Lik ^a   Gao, Yuan ^a   Zeng, Zhi Hong ^a   Zhou, Tian Hong ^a   Hong, An ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Insulin; Intein; Recombinant; VPAC2 agonist

Indexed keywords

CHITIN; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; HYBRID PROTEIN; INTEIN; PROTEIN DERIVATIVE; PROTEIN RMBAY; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2 AGONIST;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; ESCHERICHIA COLI; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN RELEASE; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PURIFICATION;

ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; FERMENTATION; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; MICE; PEPTIDE FRAGMENTS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33947657289     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00529.x     Document Type: Article

References (18)

1. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, et al. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50: 265-70.
2. Gozes I, Fridkinb M, Hill JM, Brenneman DE. Pharmaceutical VIP: prospects and problems. Curr Med Chem 1999; 6: 1019-34.
3. Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi T, et al. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci USA 1994; 91: 2679-83.
4. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, et al. A potent and highly selective VPAC2 agonist enhances glucoseinduced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 2002; 51: 1453-60.
5. Wei Y, Mojsov S. Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner. Ann N Y Acad Sci 1996; 805: 624-27.
6. Yokota C, Kawai K, Ohashi S, Watanabe Y, Yamashita K. PACAP stimulates glucose output from the perfused rat liver. Peptides 1995; 16: 55-60.
7. Yung SL, Cruz FD, Hamren S, Zhu J, Tsutsumi M, Bloom JW, et al. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem 2003; 278: 10273-81.
8. Chong S, Mersha FB, Comb DG, Scott ME, Landry D, Vence LM, et al. Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element. Gene 1997; 192: 277-81.
9. Chong S, Shao Y, Paulus H, Benner J, Perler FB, Xu MQ. Protein splicing involving the Saccharomyces cerevisiae VMA intein: the steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system. J Biol Chem 1996; 271: 22159-68.
10. Yu RJ, Xie QL, Dai Y, Gao Y, Zhou TH, Hong A. Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2. Peptides 2006; 27: 1357-66.
11. Yang LP, Kong XP, Yi XR. Analyzing peptides of low weights molecular with SDS-polyacrylamide gel electrophoresis. Prog Biotechnol 1998; 18: 19-21. Chinese
12. Yu RJ, Hong A, Dai Y, Gao Y. Intein-mediated rapid purification of recombinant human pituitary adenylate cyclase activating polypeptide. Acta Biochim Biophys Sin 2004; 36: 759-66.
13. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, Renzetti L, et al. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist, part I: in vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther 1994; 270: 1282-8.
14. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Tocker JE, Tannu SA, et al. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist, part II: effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 1994; 270: 1289-94.
15. Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, et al. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 1997; 18: 403-8.
16. Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor. Peptides 2000; 21: 1543-49.
17. Juarranz MG, Rampelbergh JV, Gourlet P, De Neef P, Cnudde J, Robberecht P, et al. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC2-selective ligands. Mol Pharmacol 1999; 56: 1280-7.
18. Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency. Peptides 2004; 25: 275-8.